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LETTERS
Inﬂ  uenza surge planning is premised 
on a high incidence of illness among 
elderly persons, but if the current pat-
tern of illness continues, healthcare 
facilities also should prepare to treat 
younger persons who may constitute 
the bulk of cases. Additionally, stud-
ies of persons born during 1957–1968
should be conducted to quantify anti-
body levels to pandemic (H1N1) 2009 
virus, focusing on the degree of preex-
isting immunity that may have existed 
and was boosted by prior encounters 
with subtype H1N1 viruses
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Swine Inﬂ  uenza A 
Vaccines, 
Pandemic (H1N1) 
2009 Virus, and 
Cross-Reactivity
To the Editor: Since its ﬁ  rst 
emergence in the human population in 
spring 2009 (1–3) infections with pan-
demic (H1N1) 2009 virus have been 
reported in pigs, turkeys, and some 
carnivore species (4,5). The pandemic 
(H1N1) 2009 virus can be experimen-
tally transmitted between pigs (6). 
The reported transmissibility of the 
virus raises the question as to whether 
authorized swine inﬂ  uenza  vaccine 
strains may be cross-reactive to pan-
demic (H1N1) 2009 virus. Kyriakis et 
al. (7) investigated the cross-reactivity 
of 66 pig serum samples from differ-
ent infection and vaccination trials and 
reported cross-reactions between the 
avian-like H1N1 viruses circulating in 
the European pig population (avH1N1) 
and the classical swine H1N1 viruses 
(cH1N1) with pandemic (H1N1) 2009 
virus by hemagglutination inhibition 
assay. 
To investigate this cross-reactivity 
in more detail, a neutralization test was 
applied in the study we report here. A 
serial dilution of serum samples was 
prepared (log4). All virus strains were 
adjusted to 100 ﬁ  fty-percent  tissue 
culture infectious doses. This work-
ing dilution of virus was mixed with 
serum dilutions and incubated 1 hour 
at 37°C. Madin-Darby bovine kid-
ney monolayers were infected with 
the neutralization mixtures. After 48 
hours of incubation, cells were ﬁ  xed 
with acetone (4°C–8°C) and investi-
gated by indirect immunoﬂ  uorescent 
assay. Finally, the 50% neutralization 
titer was calculated.
Hyperimmune serum samples 
were established by using a 4-fold vac-
cination of pigs with antigens of H1N1 
vaccine strains (A/New Jersey/8/1976, 
A/sw/Netherlands/25/1980, A/sw/
IDT/Re230/1992, A/sw/Haselünne/
IDT2617/2003), and a strain of 
pandemic (H1N1) 2009 virus (A/
Hamburg/7/2009) by using Freund ad-
juvant. Blood samples were taken 14 
days after last immunization. A vac-
cine containing the pandemic (H1N1) 
2009 virus was produced. Swine in-
ﬂ  uenza vaccines available in central 
Europe and the newly produced vac-
cine containing pandemic (H1N1) 
2009 virus (A/Hamburg/7/2009) were 
administered to pigs (2-fold vaccina-
tion with 1–2 mL of the vaccine 21–28 
days apart intramuscularly). Blood 
was withdrawn 7 days after second 
administration.
In addition, an experimental aero-
sol infection was conducted by using 
the parental strain of the most recent 
avH1N1 strain contained in a Euro-
pean swine inﬂ  uenza vaccine (A/sw/
Haselünne/IDT2617/2003). Blood 
samples were taken 10 days after in-
fection.
The investigation of the hyper-
immune serum samples detected 
neutralizing activity between the 
pandemic (H1N1) 2009 virus and 
European avH1N1 vaccine strains 
(A/sw/Netherlands/25/1980, A/sw/
IDT/Re230/1992, A/sw/Haselünne/
IDT2617/2003), as well as with the 
cH1N1 strain A/New Jersey/8/1976 
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(Fort Dix reassortant). The hyper-
immune serum established against 
pandemic (H1N1) 2009 virus also 
showed cross-reactivity with Euro-
pean avH1N1 virus. The reactions 
against several strains of the pandem-
ic virus were similar, reﬂ  ecting high 
titers against pandemic (H1N1) 2009 
virus but also cross-reactions with 
hyperimmune serum samples of all 
swine inﬂ  uenza A virus H1N1 vaccine 
strains (online Appendix Table, www.
cdc.gov/EID/content/16/6/1029-
appT.htm).
The bivalent vaccines induced 
high titers of neutralizing antibodies 
against avH1N1 virus and human-like 
H3N2 virus (huH3N2). Only a low 
number of pigs reacted with H1N2 
virus whereas the trivalent vaccine 
induced high neutralizing activity in 
serum samples of all vaccinated pigs. 
The vaccines induced neutralizing 
antibodies against pandemic (H1N1) 
2009 virus. The titers were lower 
in comparison to those obtained for 
avH1N1 and not all pigs responded. 
The reactions were best for the vac-
cines containing mineral oil. Pigs 
vaccinated with the trivalent vaccine 
with carbomer adjuvant showed al-
most no antibodies against pandemic 
(H1N1) 2009 virus, although the vac-
cine strain reacted well in hyperim-
munization tests. 
A vaccine batch of the trivalent 
vaccine was produced that contained 
mineral oil instead of carbomer. All 
pigs vaccinated with the trivalent 
vaccine with mineral oil had anti-
bodies against the pandemic (H1N1) 
2009 virus (data not shown). At the 
same time, efﬁ   cacy trials with all 
authorized vaccines were conducted 
(8; T.W. Vahlenkamp, pers. comm.) 
in which all vaccines including the 
trivalent vaccine with carbomer ad-
juvant showed a comparable level 
of protection (limited period of viral 
shedding). Mineral oil adjuvants can 
induce severe distress in pig herds 
due to their limited safety. Despite 
cross-reactivity between avH1N1 and 
cH1N1 with pandemic (H1N1) 2009 
virus, the highest degree of cross-
neutralization was achieved by the 
vaccine containing pandemic (H1N1) 
virus strain.
Proof of cross-reactivity was also 
reﬂ   ected in the infection trial. Pigs 
infected with avH1N1 responded 
to avH1N1 as well as to pandemic 
(H1N1) 2009 virus. All results were 
additionally conﬁ   rmed by hemag-
glutination inhibition assay (data not 
shown).
Furthermore, 1,559 pig serum 
samples from 195 German pig herds 
collected from mid-June through mid-
September 2009 were tested in rou-
tine diagnostics by hemagglutination 
inhibition assay. All reﬂ  ected almost 
similar results for avH1N1 and the 
pandemic (H1N1) 2009 virus (sero-
prevalences for individual pigs were 
pandemic [H1N1] 2009 virus 52%, 
avH1N1 53%, huH1N2 28%, and 
huH3N2 52%; for pig herds pandem-
ic [H1N1] 2009 virus 46%, avH1N1 
46%, huH1N2 24%, and huH3N2 
45%). These results suggest cross-re-
activity between porcine H1N1 virus-
es and pandemic (H1N1) 2009 virus. 
Despite this cross-reactivity, a vaccine 
consisting of pandemic (H1N1) 2009 
virus is superior in terms of efﬁ  cacy 
in comparison with vaccines already 
authorized in Europe. 
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